PROGRESSION-FREE SURVIVAL IS A POOR SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN THE FIRST LINE EGFR-TKI TREATMENT IN ADVANCED NON-SMALL-CELL LUNG CANCER WITH EGFR MUTATION

被引：0
|
作者：
Liao, Ri-Qiang [1 ]
Yang, Xue-Ning [2 ]
Yan, Hong-Hong [2 ]
Zhou, Qing [2 ]
Wu, Yi-Long [3 ]
Zhong, Wen Zhao [3 ]
机构：
[1] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Div Pulm Oncol, Guangzhou, Guangdong, Peoples R China
[2] Guangdong Gen Hosp, Div Pulm Oncol, Guangzhou, Guangdong, Peoples R China
[3] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
Surrogate; PFS; EGFR mutation; OS;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.11-044
引用
收藏
页码：S615 / S615
页数：1
相关论文
共 50 条
  • [31] First-line treatment and overall survival in EGFR mutation-positive advanced non-small cell lung cancer: a national cohort study
    Huang, L. -y.
    Chang, H. -p.
    Chang, R. -y.
    Tai, H. -y.
    Huang, Y. -w.
    Lee, P. -c.
    [J]. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2022, 26 (20) : 7632 - 7640
  • [32] EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer
    Thang Thanh Phan
    Bich-Thu Tran
    Son Truong Nguyen
    Toan Trong Ho
    Hang Thuy Nguyen
    Vu Thuong Le
    Anh Tuan Le
    [J]. CLINICAL AND TRANSLATIONAL MEDICINE, 2019, 8
  • [33] Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint
    Zewei Zhang
    Chunxia Xie
    Tiantian Gao
    Yuxian Yang
    Yong Yang
    Lei Zhao
    [J]. BMC Cancer, 23
  • [34] Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer
    Liu, Liya
    Yu, Hao
    Huang, Lihong
    Shao, Fang
    Bai, Jianling
    Lou, Donghua
    Chen, Feng
    [J]. OncoTargets and Therapy, 2015, 8 : 921 - 928
  • [35] EGFR-TKI rechallenged treatment combined with apatinib in non-small cell lung cancer with EGFR-TKI resistance.
    Liang, Li
    Li, Fang
    Cao, Baoshan
    Zhang, Zhaohui
    Zhu, Xiang
    Wang, Jiadong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [36] Larger tumors are associated with inferior progression-free survival of first-line EGFR-tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non-small cell lung cancer
    Pan, Yingying
    Gao, Guanghui
    Chen, Xiaoxia
    Tian, Qinrui
    Wu, Fengying
    Liu, Qian
    Wang, Yan
    Jiang, Tao
    Liu, Yiwei
    Li, Xuefei
    Yang, Shuo
    Xu, Chuan
    Su, Chunxia
    Zhou, Fei
    Ren, Shengxiang
    Zhou, Caicun
    [J]. THORACIC CANCER, 2019, 10 (04) : 686 - 694
  • [37] Divergence phenomenon of EGFR-TKI in the treatment of non small cell lung cancer
    Zhang, Xia
    Liu, Chang
    Li, Juan
    Song, Fei-xiang
    Ruan, Xin-jian
    Jia, Zhi-ling
    [J]. SCIENTIFIC RESEARCH AND ESSAYS, 2010, 5 (24): : 3967 - 3971
  • [38] Allele specific gains of EGFR predicts benefit from EGFR-TKI treatment for advanced non-small-cell
    Zhang, X.
    Hou, Y.
    Zhang, L.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 137 - 137
  • [39] Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer
    Hotta, Katsuyuki
    Suzuki, Etsuji
    Di Maio, Massimo
    Chiodini, Paolo
    Fujiwara, Yoshiro
    Takigawa, Nagio
    Ichihara, Eiki
    Reck, Martin
    Manegold, Christian
    Pilz, Lothar
    Hisamoto-Sato, Akiko
    Tabata, Masahiro
    Tanimoto, Mitsune
    Shepherd, Frances A.
    Kiura, Katsuyuki
    [J]. LUNG CANCER, 2013, 79 (01) : 20 - 26
  • [40] Effect of Combined Therapy Inhibiting EGFR and VEGFR Pathways in Non Small-cell Lung Cancer on Progression-free and Overall Survival
    Jiang, Tao
    Qiao, Meng
    Zhou, Fei
    Ren, Shengxiang
    Su, Chunxia
    Zhou, Caicun
    [J]. CLINICAL LUNG CANCER, 2017, 18 (04) : 421 - 431
12345